Replidyne is the biopharmaceutical company concentrating on discovering, developing, and in-licensing and commercializing the inventive anti-infective products. One such product is known as Orapem which is the ester prodrug derivative of Faropenem which is one of the extensively researches and studied member of the penem category and perhaps the only penem which is orally bioavailable. The prodrug form of Faropenem offers the radically increased oral bioavailability and directs to the advanced complete focus of the drug.

Faropenem medoxomil was initially licensed during March 2004, from Daiichi Suntory Pharmaceuticals which is presently known as Asubio Pharma Company Limited. Faropenem is the member of the penem subcategory from the beta-lactam group of the antibiotics which is the distinct group of artificial beta-lactam which are the structural crossbreed penicillin – penams and cephalosporin – cephams. Faropenem medoxomil is the original oral penem antibiotic that has reached the highest phase of clinical development in the United States and also it is under development for community-acquired respiratory infections. The community antibiotics are by and large used for treating infections acquired out side of the hospitals.   
   
Faropenem medoxomil is the prodrug which is transformed into the active drug Orapem – Faropenem through the metabolic procedure within the body. Orapem enters the bacteria cell and binds with the penicillin binding proteins – PBP that are bound with membrane enzymes of the cytoplasmic membranes. Penicillin Binding Proteins – PBP play the vital role in cell wall biosynthesis and their reticence is the fatal episode. Orapem – Faropenem has certain matchless qualities which differentiates it from the other beta-lactam.